Cambridge, MA, United States of America

Ethan R Signer

USPTO Granted Patents = 12 

Average Co-Inventor Count = 9.5

ph-index = 8

Forward Citations = 490(Granted Patents)


Company Filing History:


Years Active: 1998-2010

Loading Chart...
12 patents (USPTO):Explore Patents

Title: Innovations of Ethan R Signer

Introduction

Ethan R Signer is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of amyloid aggregation research. With a total of 12 patents to his name, he has made strides in developing compounds that can modulate the aggregation of amyloidogenic proteins and peptides. His work is crucial in the fight against amyloidogenic diseases.

Latest Patents

Signer’s latest patents include innovative compounds that modulate amyloid aggregation. One of his notable inventions involves compounds that can either promote or inhibit the aggregation of natural β-amyloid peptides. These modulators are designed to alter the aggregation or inhibit the neurotoxicity of natural β-amyloid peptides when they come into contact with them. Additionally, he has developed modulators comprising D-amino acids that specifically target natural β-amyloid peptide aggregation. These compounds are essential for creating pharmaceutical compositions and diagnostic methods for treating amyloidogenic diseases.

Career Highlights

Ethan R Signer is currently associated with Praecis Pharmaceuticals, Inc., where he continues to innovate in the field of pharmaceutical research. His work has garnered attention for its potential impact on therapeutic approaches to amyloid-related conditions.

Collaborations

Signer has collaborated with notable colleagues, including Malcolm L Gefter and Mark A Findeis, who have contributed to his research endeavors and the development of his patented technologies.

Conclusion

Ethan R Signer’s contributions to the field of amyloid aggregation research highlight his role as a leading inventor in the pharmaceutical industry. His innovative patents and ongoing work at Praecis Pharmaceuticals, Inc. continue to pave the way for advancements in treating amyloidogenic diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…